Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Operations: 2014-2025

Historic Cash from Operations for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$84.6 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Operations fell 24.97% to -$84.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.0 million, marking a year-over-year decrease of 65.48%. This contributed to the annual value of -$232.3 million for FY2024, which is 26.14% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Cash from Operations of -$84.6 million as of Q3 2025, which was down 12.26% from -$75.4 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Cash from Operations high stood at -$11.5 million for Q1 2021, and its period low was -$92.7 million during Q1 2025.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Cash from Operations had a median value of -$62.0 million in 2023 and averaged -$60.8 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Cash from Operations crashed by 194.52% in 2023 and then climbed by 27.03% in 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Operations (Quarterly) stood at -$16.5 million in 2021, then plummeted by 105.88% to -$34.0 million in 2022, then dropped by 11.63% to -$38.0 million in 2023, then crashed by 92.98% to -$73.3 million in 2024, then dropped by 24.97% to -$84.6 million in 2025.
  • Its last three reported values are -$84.6 million in Q3 2025, -$75.4 million for Q2 2025, and -$92.7 million during Q1 2025.